OP
CBPO

Omni Partners’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Omni Partners’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$3.8M Sell
32,065
-5,305
-14% -$627K 0.19% 60
2020
Q4 		$4.41M Buy
+37,370
New +$4.34M 0.26% 88

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Omni Partners's CBPO Position: Q1 2021 in Review

Omni Partners reduced its China Biologic Products Holdings, Inc. (CBPO) stake by 14% in Q1 2021, selling an estimated $627K and leaving 32,065 shares worth $3.8M. The position accounts for 0.19% of the portfolio, ranked #60.

Omni Partners first reported a position in CBPO in Q4 2020 and has held it in 2 quarters since. The position peaked at $4.41M in Q4 2020. 86 funds tracked by Wall St. Rank hold CBPO as of Q1 2021.

  • Omni Partners held 32,065 shares of China Biologic Products Holdings, Inc. worth $3.8M as of Q1 2021.
  • Omni Partners sold 5,305 China Biologic Products Holdings, Inc. shares in Q1 2021, an estimated $627K.
  • China Biologic Products Holdings, Inc. made up 0.19% of Omni Partners's portfolio in Q1 2021, its #60 holding.
  • Omni Partners first reported a position in China Biologic Products Holdings, Inc. in Q4 2020 and has held it in 2 quarters since.
  • Omni Partners's China Biologic Products Holdings, Inc. position peaked at $4.41M in Q4 2020.
  • 86 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2021.

Based on Omni Partners's 13F filing for Q1 2021, filed 17 May 2021.